<DOC>
	<DOCNO>NCT01204684</DOCNO>
	<brief_summary>The main purpose study evaluate effective immunotherapy vaccine component patient malignant glioma . Teh investigator previous phase I study ( IRB # 03-04-053 ) already confirm vaccine procedure safe patient malignant brain tumor , indication extend survival several patient . However , previous trial design allow u test formulation vaccine effective . This phase II study attempt dissect component effective together . Dendritic cell ( DC ) ( cell `` present '' `` show '' cell identifier immune system ) isolate subject 's blood treat tumor-cell lysate isolate tumor tissue take subject surgery . This pulsing ( combine ) antigen-presenting tumor lysate do try stimulate immune system recognize destroy patient 's intracranial brain tumor . These pulse DCs inject back patient intradermally vaccine . The investigator also utilize adjuvant imiquimod poly ICLC ( interstitial Cajal-like cell ) treatment cohort . It think host immune system might teach `` recognize '' malignant brain tumor cell `` foreign '' body effectively present unique tumor antigens host immune cell ( T-cells ) vivo .</brief_summary>
	<brief_title>Dendritic Cell Vaccine Patients With Brain Tumors</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Poly ICLC</mesh_term>
	<criteria>PATIENT ELIGIBILITY Inclusion Criteria 1 . Patients newly diagnose recurrent glioma WHO Grade III IV { anaplastic astrocytoma ( AA ) , anaplastic astrooligodendroglioma ( AO ) , glioblastoma ( GBM ) } eligible protocol . 2 . Patients must surgical resection UCLA ( University California , Los Angeles ) , separate inform consent sign collection tumor prior surgery . 3 . After surgery , pathological diagnosis malignant glioma ( WHO Grade III IV ) need establish . 4 . Patients must 18 year older able read understand inform consent document . Patients must sign informed consent indicate aware investigational nature study . 5 . Patients must Karnofsky performance status ( KPS ) rating &gt; 60 prior initiate treatment . Patients may enrol KPS &lt; 60 felt patient adequate opportunity recover KPS &gt; 60 initiation treatment . Exclusion Criteria 1 . Subjects active infection . 2 . Inability obtain informed consent psychiatric complicate medical problem . 3 . Unstable severe intercurrent medical psychiatric condition determine Investigator . 4 . Females childbearing potential pregnant lactate use approved contraception . 5 . History immunodeficiency ( e.g. , HIV ) autoimmune disease ( e.g. , rheumatoid arthritis , systemic lupus erythematosus , vasculitis , polymyositisdermatomyositis , scleroderma , multiple sclerosis , juvenileonset insulindependent diabetes ) may exacerbate immunotherapy . 6 . Subjects organ allograft . 7 . Inability unwillingness return require visit followup exam . 8 . Subjects uncontrolled systemic malignancy remission .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>dendritic cell</keyword>
	<keyword>glioma</keyword>
	<keyword>vaccine</keyword>
	<keyword>glioma WHO Grade III IV</keyword>
</DOC>